rs121917733
|
|
|
0.010 |
GeneticVariation |
BEFREE |
None of the 57 follicular adenomas, 26 papillary carcinomas (PCs), 7 follicular carcinomas, or the anaplastic carcinoma harbored the PKCalpha 881A>G mutation.
|
11994357 |
2002 |
rs199901715
|
|
|
0.010 |
GeneticVariation |
BEFREE |
None of the 57 follicular adenomas, 26 papillary carcinomas (PCs), 7 follicular carcinomas, or the anaplastic carcinoma harbored the PKCalpha 881A>G mutation.
|
11994357 |
2002 |
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
All three papillary carcinomas accompanied by anaplastic carcinoma with a BRAF V600E mutation were also shown to have a BRAF V600E mutation.</span>
|
17453004 |
2007 |
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
All three papillary carcinomas accompanied by anaplastic carcinoma with a BRAF V600E mutation were also shown to have a BRAF V600E mutation.</span>
|
17453004 |
2007 |
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Clinicopathologic significance of BRAF V600E mutation in papillary carcinomas of the thyroid: a meta-analysis.
|
17520704 |
2007 |
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Clinicopathologic significance of BRAF V600E mutation in papillary carcinomas of the thyroid: a meta-analysis.
|
17520704 |
2007 |
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
BRAF V600E mutation and p27 kip1 expression in papillary carcinomas of the thyroid <or=1 cm and their paired lymph node metastases.
|
17685465 |
2007 |
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
BRAF V600E mutation and p27 kip1 expression in papillary carcinomas of the thyroid <or=1 cm and their paired lymph node metastases.
|
17685465 |
2007 |
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The missense point mutation BRAF(V600E) was identified in 42% (13/31 cases) of papillary carcinomas and 33% (5/15 cases) of undifferentiated carcinomas but not in normal thyroid tissues, nodular hyperplasia, follicular adenomas, or follicular carcinomas.
|
17714762 |
2007 |
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The missense point mutation BRAF(V600E) was identified in 42% (13/31 cases) of papillary carcinomas and 33% (5/15 cases) of undifferentiated carcinomas but not in normal thyroid tissues, nodular hyperplasia, follicular adenomas, or follicular carcinomas.
|
17714762 |
2007 |
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
These findings indicate that, although BRAF(V600E) mutation may play some roles in local carcinoma development, there is no evidence that BRAF(V600E) mutation significantly reflects the aggressive characteristics and poor prognosis of patients with papillary carcinoma in Japan.
|
18840924 |
2009 |
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
These findings indicate that, although BRAF(V600E) mutation may play some roles in local carcinoma development, there is no evidence that BRAF(V600E) mutation significantly reflects the aggressive characteristics and poor prognosis of patients with papillary carcinoma in Japan.
|
18840924 |
2009 |
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The T1799A BRAF mutation is absent in cribriform-morular variant of papillary carcinoma.
|
19415957 |
2009 |
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
A high percentage of both melanomas and papillary carcinomas of the thyroid harbors a recurrent mutation (i.e., BRAF(V600E) ) in the BRAF oncogene.
|
24574369 |
2014 |
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
A high percentage of both melanomas and papillary carcinomas of the thyroid harbors a recurrent mutation (i.e., BRAF(V600E) ) in the BRAF oncogene.
|
24574369 |
2014 |
rs121913364
|
|
|
0.010 |
GeneticVariation |
BEFREE |
The c.1801A>G mutation was identified in 4 follicular variant papillary carcinomas and one follicular carcinoma.
|
25120313 |
2014 |
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The BRAF V600E mutation was detected in 68 % (71/104) of papillary carcinoma cases and 78 % (7/9) of anaplastic carcinoma cases.
|
25894433 |
2015 |
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The BRAF V600E mutation was detected in 68 % (71/104) of papillary carcinoma cases and 78 % (7/9) of anaplastic carcinoma cases.
|
25894433 |
2015 |
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Given the strong genotype:phenotype correlation known to be present in thyroid cancer, the separation of BRAF(V600E)-like and RAS-like tumors has profound implications for its classification, especially the follicular variant of papillary carcinoma.
|
26569424 |
2016 |
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Given the strong genotype:phenotype correlation known to be present in thyroid cancer, the separation of BRAF(V600E)-like and RAS-like tumors has profound implications for its classification, especially the follicular variant of papillary carcinoma.
|
26569424 |
2016 |
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Next generation sequencing showed BRAF V600E mutation in the primary papillary carcinoma and NRAS Q61R mutation in the primary follicular carcinoma and bony metastasis.
|
28710706 |
2018 |
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Next generation sequencing showed BRAF V600E mutation in the primary papillary carcinoma and NRAS Q61R mutation in the primary follicular carcinoma and bony metastasis.
|
28710706 |
2018 |
rs1057519695
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Next generation sequencing showed BRAF V600E mutation in the primary papillary carcinoma and NRAS Q61R mutation in the primary follicular carcinoma and bony metastasis.
|
28710706 |
2018 |
rs1057519834
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Next generation sequencing showed BRAF V600E mutation in the primary papillary carcinoma and NRAS Q61R mutation in the primary follicular carcinoma and bony metastasis.
|
28710706 |
2018 |
rs11554290
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Next generation sequencing showed BRAF V600E mutation in the primary papillary carcinoma and NRAS Q61R mutation in the primary follicular carcinoma and bony metastasis.
|
28710706 |
2018 |